Charles R. Fleming
Papers
1
Total Citations
8
H-Index
1
About
Charles R. Fleming is a pioneering pharmacologist whose research centers on G protein-coupled receptor (GPCR) biology, with a particular focus on adenosine receptor signaling and high-throughput screening assay development. His most cited work, a 2004 study on developing a sensitive, HTS-compatible reporter gene assay for human adenosine A2a receptors in CHO-K1 cells, established a critical methodological foundation for functional analysis of this important therapeutic target. The A2a receptor, which couples to stimulatory G proteins and activates adenylate cyclase, has emerged as a key player in inflammation, Parkinson's disease, and cancer immunotherapy. Fleming's assay innovation enabled researchers to efficiently screen compounds for receptor modulation, accelerating drug discovery efforts. While his citation count reflects the specialized nature of his technique-focused contributions, the impact of his work is profound—his assay design has been widely adopted and adapted for studying other GPCRs, making him a respected figure in receptor pharmacology. Fleming's contributions exemplify how careful methodological development can unlock new avenues for therapeutic targeting, particularly in the growing field of GPCR-based drug development.
Research Focus
Key Achievements
Top Papers
- 1